Kura Oncology, Inc.
NASDAQ:KURABiotechnology
Healthcare
$7.35 +0.73%
+$0.07 today
- Market cap
- $675.31M
- Beta
- 0.36
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.32
52W Low $5.45High $12.49
Volume 1.66M
Average 1.66M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$64.06M
FY 2025 · Annual
Investing Cash Flow
-$13.10M
FY 2025 · Annual
Financing Cash Flow
$1.79M
FY 2025 · Annual
-98.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (130.47M) | (135.84M) | (152.63M) | (173.98M) | (278.67M) |
| Depreciation & Amortization | 558K | 759K | 849K | 848K | (7.46M) |
| Deferred Income Tax | 4.6M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 23.58M | 26.32M | 28.08M | 33.9M | 37.11M |
| Change in Working Capital | (3.22M) | (2.98M) | 7.82M | 286.17M | 184.44M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (6.74M) |
| Inventory | 0 | 0 | 0 | 0 | (413K) |
| Accounts Payables | (2.52M) | (802K) | 10.33M | 15.2M | 4.5M |
| Other Working Capital | (706K) | (2.18M) | (2.51M) | 270.97M | 187.1M |
| Other Non-Cash Items | 399K | 1.68M | (8.94M) | (12.62M) | 515K |
| Operating Cash Flow | (104.55M) | (110.06M) | (124.82M) | 134.32M | (64.06M) |
| Capital Expenditures | (1.15M) | (626K) | (168K) | (472K) | (6.64M) |
| Acquisitions (Net) | 125.69K | (33.25K) | 0 | 0 | 0 |
| Purchases of Investments | (445.66M) | (270.66M) | (409.82M) | (659.05M) | (761.59M) |
| Sales of Investments | 319.97M | 303.91M | 425.55M | 557.93M | 755.13M |
| Other Investing Activities | (125.69K) | 33.25K | 0 | 0 | 0 |
| Investing Cash Flow | (126.84M) | 32.63M | 15.56M | (101.59M) | (13.1M) |
| Debt Repayment | (7.25M) | 10M | 0 | 0 | 0 |
| Common Stock Issued | 4.43M | 24.72M | 93.58M | 145.81M | 1.79M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (611K) | 3.84M | 1.21M | 8.6M | 0 |
| Financing Cash Flow | (3.44M) | 38.57M | 94.78M | 154.42M | 1.79M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (234.82M) | (38.87M) | (14.48M) | 187.14M | (75.36M) |
| Free Cash Flow | (105.7M) | (110.69M) | (124.99M) | 133.85M | (70.7M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$278.7M
+ D&A-$7.5M
+ Stock-Based Comp$37.1M
+ Deferred Tax$0
+ Working Capital$184.4M
+ Other Non-Cash$515.0K
= Operating Cash Flow-$64.1M
- Capex-$6.6M
= Free Cash Flow-$70.7M
Analysis
FY2025 free cash flow is -$70.7M. FCF conversion is 25.4% of net income. Operating cash flow was -$64.1M, with capex of -$6.6M. The largest bridge item is Working Capital at $184.4M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-3ASR | S-3ASR filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 29, 2026 |
Does KURA generate free cash flow?
Kura Oncology, Inc. (KURA) generated -$70.70M of free cash flow in fiscal 2025.
How much operating cash flow does KURA produce?
Operating cash flow was -$64.06M, before capital expenditures of $6.64M.
Continue the stock analysis
Jump to another research area for this company.